Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
NCT02750930
Terminated
Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US) Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory agencies. This is a 26 week, open-label, single group, multicenter, extension study to Study 200952. This extension study will provide extended safety, tolerability and immunogenici... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/11/2019
Locations: GSK Investigational Site, Phoenix, Arizona +26 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
NCT02683746
Completed
This is a phase III, randomized, double-blind, multicenter, parallel group, repeat-dose, study of 26 weeks duration to evaluate the efficacy, safety, tolerability and pharmacodynamic response of albiglutide liquid drug product relative to the commercial lyophilized drug product. The study will specifically evaluate the potential for immunogenicity (example \[e.g.\] incidences of anti-drug antibodies \[ADA\]) and injection site reactions (ISRs). Albiglutide is a novel analogue of glucagon-like p... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/10/2019
Locations: GSK Investigational Site, Birmingham, Alabama +69 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
NCT02465515
Completed
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/11/2019
Locations: GSK Investigational Site, Birmingham, Alabama +607 locations
Conditions: Diabetes Mellitus
Register for Updates
A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
NCT03015519
Withdrawn
The incidence of Type 2 Diabetes Mellitus (T2DM) is increasing day by day but the treatment options are limited in children and adolescents. Albiglutide, approved for the treatment of T2DM in adult population, is a novel analogue of glucagon-like peptide-1 (GLP-1) with a sufficiently long half-life to permit once a week injection. The study will be conducted in 2 parts: Part A is a single dose pharmacokinetic (PK) study to confirm the dose and safety of albiglutide in pediatric subjects aged 10... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
01/16/2019
Locations: GSK Investigational Site, Chicago, Illinois +2 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
NCT02496221
Completed
Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus. The primary objective of this study is to assess if a single dose of albiglutide can affect cholecystokinin-induced gallbladder emptying. To make this assessment, each study participant will receive a dose of albiglutide and a dose of placebo followed by cholecystokinin (CCK) infusion and ultrasound measurement of the gallbladder. The study will be com... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/09/2018
Locations: GSK Investigational Site, Baltimore, Maryland
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT03249506
Completed
The purpose of this study is to identify and evaluate the event rate of the composite endpoint of all-cause mortality (ACM) or hospitalization for heart failure (HF) for participants with Type 2 Diabetes mellitus (T2DM) and established cardiovascular (CV) disease among new users of sodium-glucose co-transporter 2 inhibitor (SGLT2i) as compared with new users of non-SGLT2i anti-hyperglycemic agent (AHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/17/2017
Locations: Health ResearchTx, LLC, Trevose, Pennsylvania
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
NCT00938158
Completed
The purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects requiring hemodialysis.
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
07/18/2017
Locations: GSK Investigational Site, Anniston, Alabama +6 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery
NCT00966654
Terminated
This research is being done to see if giving a hormone called GLP-1 can improve heart function and reduce length of stay in the Cardiac Surgical Intensive Care Unit (CSICU) in people who have non-emergent coronary artery bypass graft (CABG) surgery.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/29/2017
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: CABG
Register for Updates
A Drug Interaction Study With Albiglutide and Warfarin
NCT01147731
Completed
This open-label study evaluates the pharmacokinetics of warfarin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of warfarin.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
06/21/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
NCT01077505
Completed
This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
06/13/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Drug Interaction Study of Albiglutide and Digoxin
NCT01147718
Completed
This Phase I, open-label, sequential, single-center study evaluates the pharmacokinetics of digoxin when coadministered with albiglutide in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/09/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Drug Interaction Study of Simvastatin and Albiglutide
NCT01147692
Completed
This open-label study evaluates the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects. The primary objective is to assess the effect of albiglutide doses on the pharmacokinetics of simvastatin.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/07/2017
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates